Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IPAB Repeal Bill On Way To House Vote

This article was originally published in The Pink Sheet Daily

Executive Summary

A bill to repeal provisions creating the Independent Payment Advisory Board clears two House panels. CBO says repeal could increase federal spending by $3.1 billion over 10 years but adds caveat that the actual impact is “extremely uncertain.”

You may also be interested in...

Delaying Medicaid Expansion Could Be Source Of Savings In Deficit Talks – Rep. Burgess

Texas Republican Congressman Burgess suggests that provisions of the Affordable Care Act, including delaying the Medicare expansion, need to be on the table to help address the budget deficit, including raising the debt ceiling.

IPAB Raised At Debate, But Romney Advisor Skeptical Board Will Meet Even If Obama Wins

Strict conflict-of-interest restrictions will make it very challenging to get people confirmed to serve on the Independent Payment Advisory Board established under the 2010 health reform law, according to a top health care advisor to Mitt Romney. IPAB was addressed in the Oct. 3 presidential debate.

Antibiotics Stewardship Remains Open Question On Capitol Hill

FDA’s role in the practice of medicine becomes an issue as IDSA’s proposal to spur antibiotic development by coupling small trials with limited use comes late to the antibiotic incentives debate on Capitol Hill.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts